PATENT CLAIM ANALYSIS

Application Number: 15884221
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["435", "006100"]

Abstract:
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising obtaining a biological sample from the patient having the hematological cancer; determining the expression level of one, two, three, four, five, or more genes; and comparing the expression level of the one, two, three, four, five, or more genes in the biological sample with a reference expression level of the same genes, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Claim (Index 68):
The method of  claim 52 , wherein the expression level of one, two, three, four, five, or more of the genes selected from the group consisting of C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CILP, CIRH1A, CLU, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, LRP11, MEGF6, MEIS1, PLAT, SERPING1, SPC25, THEMIS2, TPSAB1, ULK1, XAF1, and ZNF215 are determined and compared.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 2.15
- Patent Class: 435.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15273205', '13459005', '15150227', '14381004', '13417088']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6157519444223485
- 35 USC 102 Novelty (BERT): 0.6133736196781727
- Combined Prediction Score: 0.6155141119479309
- Mean Citation Score: 308.514826
- Max Citation Score: 598.8112
- Similarity Product: 489.7506566291809

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test